MethylGene Inc.

MethylGene Inc.

November 29, 2007 07:30 ET

MethylGene to Present Clinical Data for MGCD0103 at the 49th Annual Meeting of the American Society of Hematology

MONTREAL, QUEBEC--(Marketwire - Nov. 29, 2007) - MethylGene Inc. (TSX:MYG) today announced that clinical results for its isotype-specific, histone deacetylase (HDAC) inhibitor, MGCD0103, currently in Phase II development with the Company's partner Pharmion Corporation (NASDAQ:PHRM), will be presented in one oral and two poster presentations at the American Society of Hematology (ASH) 2007 Annual Meeting held in Atlanta from December 8 to 11, 2007.

Data being presented are from three separate MGCD0103 clinical trials: a Phase I/II combination trial with Vidaza® in patients with acute myelogenous leukemia and myelodysplastic syndrome (Trial 005), a Phase II single-agent trial in diffuse large B-cell and follicular lymphomas (Trial 008); and a Phase II single-agent trial in relapsed or refractory Hodgkin lymphoma (Trial 010).

MGCD0103 Clinical Data Oral Session

Title: Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone
Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-
Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- Trial 005
Abstract ID: 444
Guillermo Garcia-Manero, MD., et al.
Session: Acute Myeloid Leukemias: Therapy, Excluding Transplantation -
Novel Therapies
Oral Presentation: Monday, December 10, 2007 at 2:45pm, Rooms A411 and A412

MGCD0103 Clinical Data Poster Sessions

Title: Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-
Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a
Phase II Study - Trial 008
Abstract ID: 2571
Anas Younes, MD., et al.
Session: New Agents and Treatment Approaches in Non-Hodgkin Lymphoma
Poster Board: 761-II
Time: Sunday, December 9, 2007 from 6:00pm to 8:00pm, Hall B4

Title: Isotype-selective HDAC Inhibitor MGCD0103 Decreases Serum TARC
Concentrations and Produces Clinical Responses in Heavily Pretreated
Patients with Relapsed Classical Hodgkin Lymphoma (HL) - Trial 010
Abstract ID: 2566
Anas Younes, MD., et al.
Session: New Agents and Treatment Approaches in Non-Hodgkin Lymphoma
Poster Board: 756-II
Time: Sunday, December 9, 2007 from 6:00pm to 8:00pm, Hall B4

About MethylGene

MethylGene Inc. (TSX:MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza®, Gemzar® and Taxotere®. MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical programs: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; and a sirtuins program for cancer. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but are not limited to, the timing and effects of regulatory action; the continuation of collaborations; the impact of unilateral decisions and/or strategies of our collaborators; the results of clinical trials; the ability to demonstrate pharmacokinetic / bioequivalency; the timing of enrollment or completion of clinical trials; the success, efficacy or safety of MGCD0103, MGCD265 or MGCD290; the ability to scale up, formulate and manufacture sufficient GMP, clinical or commercialization quantities of MGCD0103, MGCD265 or MGCD290, and the relative success or the lack of success in developing and gaining regulatory approval and/or market acceptance for any compound or new product including MGCD0103, MGCD265 or MGCD290. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, which you are urged to read, as described in MethylGene's Annual Information Form for the fiscal year ending December 31, 2006, under the heading 'risk factors,' the final prospectus filed on February 23, 2007, and all other documents filed by the Company that can be found at Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation. These statements speak only as an update on the date they are made and MethylGene is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.

Contact Information